Last January 18th, IDAL members Juan José Garcés, José D. Martín and Fernando Mateo were giving a seminar at the renowned European Centre for Nuclear Research (CERN). Within the framework of the joint collaboration between IDAL and CERN that has been carried out the two past years, the seminar dicussed the feasibility of applying Machine Learning (ML) to automatically recognize mass spectra for UHV systems. The achieved results suggest that ML is indeed appropriate to deal with the problem and open up a window for more through analyses in the near future.
IDAL members José D. Martín, Juan Gómez, Pablo Escandell and José Mª Martínez participated in the review meeting of SMARTPIF project (www.smartpif.eu) that was held at INESCOP premises (Elda, Alicante) last March 11th. All SMARTPIF partners, the Project Officer and an external reviewer attended this meeting with the purpose of assessing the work already done in the project and the plans for the second period.
IDAL is participating in the project entitled “Smart tools for the Prescription of orthopaedic Insoles and Footwear (SMARTPIF)”, that will officially start next May, 1st. SMARTPIF was proposed in the FP7 within a call focused on research for SMEs, being very recently approved and signed by the European Comission. The duration of the project is two years, and our partners in this adventure will be the Spanish companies “Unidad de Pie Diabético S.L.” (project’s coordinator) and “Alu Group, S. L.”, the British company “Biomech Tecnologies International Limited”, the Italian company “Eurosuole SPA”, the Luxembourg company “Lion Systems”, the Spanish technological institute “Instituto Tecnológico del Calzado y Conexas”, the British “University of Salford” and the Italian “Università Politecnica delle Marche”.
In the frame of the EFIS project, IDAL has presented some result of Energetic Efficiency applied to Intelligent Buildings. These research has caught the attention of local newspapers, and this week has been published an interview with the research team. You can see the news here.
IDAL has signed an agreement with Tissat, a Spanish company focused in new technologies. IDAL will provide support and know-how in Collaborative Crowd Computing that Tissat will offer as a business service at its Data Center Walhalla, one of the biggest private data centers in Spain.
The Universitat de València representing IDAL, the Valencian Conselleria de Sanitat and the company Nephrocare E-Services Spain (subsidiary of the German multinational Medical Care) have signed an agreement to develop a computer system which will improve patients’ assistance and diagnosis –especially for those suffering from kidney diseases. This computer system, which will reduce health expenditure at the same time, will include algorithms provided by our institution.
Among other, the following figures have been present in the agreement signing: the Universitat’s Principal, Esteban Morcillo; the Valencian ministers for health and education, Luis Rosado and María José Catalá; the general director on Fresenius Medical Care Spain, Ricardo Arias; the Vice-Principal for Research, Pedro Carrasco; and the Parc Científic’s director, Antonio Raga.
Yu can read the complete news at www.uv.es
IDAL is today at the main page of the University of Valencia. IDAL has developed, using machine learning techniques and intelligent data analysis, a software application which predicts the probability of angina pectoris when patient arrives to Emergency Services at hospital. The application has been validated by the University Clinic Hospital of Valencia, and now it is being used as screening tool to categorize the seriousness of the patient at the emergency desk.
University of Valencia recognizes one more time the research task that IDAL is carrying out by publishing the news on its web page. Several Spanish newspaper have published the news too.
Idal has signed a initial contract of research with an important multinational of adversing for applyin Machine Learning to publicity campaigns. Preliminar results have been yielded recently, and currently future research is bein discussed.
IDAL has signed a contract with a private, multinational pharmaceutical company for optimize the dose drug administration. The contract will last for two years (2008-2009) and includes helping personal. Technical data is confidential.